Published 2 months ago

Reckitt suffers £7bn share price fall as baby formula lawsuits mount

Summary by Ground News

Consumer goods giant Reckitt has suffered a £7bn share price slump after it lost a US legal case claiming its baby formula contributed to the death of a premature child. FTSE 100-constituent Reckitt has now been ordered to pay Ms Watson $60m (£47m) after losing the case.

0 Articles

All

Left

Center

Right

Reuters

Reckitt to challenge $60 mln baby formula verdict, shares sink

Reckitt Benckiser (RKT.L), opens new tab said on Friday it would pursue all options to have a $60 million verdict overturned in a lawsuit related to its Enfamil baby formula in the United States as it stood by the safety of all its products.

2 months ago·United Kingdom

Read Full Article

The Telegraph

Reckitt suffers £7bn share price fall as baby formula lawsuits mount

Consumer goods giant Reckitt has suffered a £7bn share price slump after it lost a US legal case claiming its baby formula contributed to the death of a premature child.

2 months ago·London, United Kingdom

Read Full Article

The Times

Baby death ruling wipes £7bn off Reckitt’s value

Consumer goods group plans to challenge order to pay damages in Enfamil infant formula case

2 months ago·London, United Kingdom

Read Full Article

Bloomberg

Reckitt Falls After $60 Million Jury Verdict Over Formula

Reckitt Benckiser Group Plc plunged 15% after a jury awarded an Illinois woman $60 million in damages, saying the company’s Enfamil baby formula led to the death of her premature baby.

2 months ago·United States

Read Full Article

Devdiscourse

Health News Roundup: US FDA expands use of Bristol Myers' cancer therapy; Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois and more

Health News Roundup: US FDA expands use of Bristol Myers' cancer therapy; Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois and more Following is a summary of current health news briefs.US FDA expands use of Bristol Myers' cancer therapyThe U.S. Food and Drug Administration on Thursday expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the second a…

2 months ago

Read Full Article

MarketWatch

Here’s what families need to know after a landmark $60 million verdict in baby-formula suit

One family’s verdict in a baby-formula lawsuit brings hope for other families whose newborns contracted digestive diseases, though they’re not guaranteed to see the same success.

2 months ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year